Novo Nordisk NVO stock prediction: $64 bull vs $32 bear

Novo Nordisk raised its full-year outlook twice in 2026 and the stock is down 26% from its January peak. That combination is the whole investment case, in either direction. On 4 August the shares fell 6% on 47.5 million ADRs, the heaviest volume of the past year, and the headline everywhere was that the Wegovy pill had missed sales estimates. It had – by about 100 million Danish kroner, roughly $15 million on a 3.2 billion kroner line. A 3% shortfall on one product in one quarter did not erase $12 billion of market value.

What did was a number almost nobody put in a headline. Goldman Sachs analyst James Quigley cut his peak sales forecast for CagriSema, Novo’s next-generation obesity candidate, from $11.8 billion to $5 billion – a $6.8 billion revenue line removed from the model, which took roughly 6% off his topline and 10% off his operating profit estimates across 2026 through 2030, and prompted a downgrade to Neutral. Having watched a fair number of pharma selloffs get attributed to the wrong line item, this is a clean example: the market repriced a pipeline, not a quarter, and the commentary chased the smaller number because it was the one in the earnings release.

Key facts

• ADR price: $47.26 close on 7 August 2026, up 2.81% on the day and up 2.8% across the two sessions since the print; 26.1% below the 26 January peak of $63.98 – StockAnalysis, 7 Aug 2026
• Q2 2026 results, 4 August: net sales DKK 78,488 million (+3% at CER), adjusted operating profit DKK 33,389 million (+11% at CER), adjusted sales growth 7% at CER – Novo Nordisk company announcement, 4 Aug 2026
• Guidance raised: 2026 adjusted sales and adjusted operating profit growth now both seen at 0% to -6% at CER, improved from a steeper prior forecast, driven by higher GLP-1 expectations – Novo Nordisk company announcement, 4 Aug 2026
• Impairments: non-cash charges of DKK 6.3 billion in Q2 2026 on intangible pipeline assets, including DKK 4.0 billion for monlunabant; a further ZEUS-related non-cash impairment is expected in Q3 2026 – Novo Nordisk, 31 Jul and 4 Aug 2026
• The two shocks: 31 July -8.8% on a late-stage heart-drug trial miss, then 4 August -6.0% on 47.5 million ADRs, the year’s heaviest volume – Nasdaq historical data, Aug 2026
• CagriSema downgrade: Goldman cut peak sales from $11.8 billion to $5 billion, trimming operating profit estimates ~10% for 2026-2030 – Goldman Sachs via TIKR, Aug 2026
• Wegovy pill: Q2 sales of 3.2 billion kroner (about $500 million) against a 3.3 billion kroner FactSet consensus – CNBC, 5 Aug 2026
• Prescription velocity: the first million pill prescriptions took 11 weeks without competition; the most recent million took four weeks with it, on 5 million cumulative – CNBC, 5 Aug 2026
• Earnings: quarterly EPS of $1.02, $1.00, $1.04 and $0.96 – a beat in each of the last four quarters – against forward consensus of $0.79 and $0.82 – Nasdaq consensus and actuals, Aug 2026
• Street target: consensus $47.32 across 14 analysts – just 0.1% above the $47.26 close – with a $63.79 high and a $40.41 low, consensus rating Buy – S&P Global via StockAnalysis, 7 Aug 2026
• Post-results analyst moves: BMO Capital’s Evan Seigerman raised his target to $47 from $45 while keeping Market Perform; Citi cut to DKK 310 from DKK 330; Goldman Sachs remains at Hold after its CagriSema downgrade – TipRanks and Benzinga, Aug 2026
• Market capitalisation: $208.61 billion; 52-week ADR range $35.12 to $64.16 – StockAnalysis, 7 Aug 2026

A mega-cap trading like a biotech

Here is the statistic that frames everything else. In the last twelve months, a $208 billion pharmaceutical company has had four separate single-day drops of 8% or more: -14.6% on 3 February, -16.4% on 23 February, -8.8% on 31 July and -6.0% on 4 August. Blue-chip pharma does not trade like this. That is a binary-event volatility profile, the kind you expect from a clinical-stage biotech with one asset in Phase 3, not from the company that built the GLP-1 category.

The reason is that Novo’s valuation now rests on pipeline outcomes rather than on the installed base. Ozempic and Wegovy are established, and their economics are increasingly well understood. What is not settled is whether Novo has a credible answer to Eli Lilly in the next generation. Every readout that speaks to that question moves the stock by a year’s worth of normal volatility in a single session.

February set the pattern: the shares sank 16% when CagriSema failed to match Lilly’s tirzepatide in a head-to-head trial in Type 2 diabetes patients. July and August repeated it, first on the heart-drug trial and then on the combination of the Q2 print and further mixed CagriSema data. The market has learned to treat each Novo readout as a referendum on the company’s post-semaglutide future, and it is pricing accordingly.

The selloff has been fully retraced – and almost nobody noticed

The most important development since the print is the one that generated no headlines at all. NVO closed at $47.26 on 7 August, up 2.81% on the day and up 2.8% from where it sat immediately before the Q2 results. The 6% drop on 4 August and the 8.8% ZEUS drop on 31 July have, in aggregate, been unwound. The stock is now trading above its pre-ZEUS level.

That is a meaningful signal in a name whose entire volatility profile is event-driven. When a pipeline stock gaps down on trial data and then recovers the whole move inside a week, the market is telling you the initial reaction over-weighted the readout. It does not mean the readout was good – ZEUS missed its primary endpoint with a hazard ratio of 0.99 and a confidence interval of 0.88 to 1.11, which is about as flat a result as a cardiovascular outcomes trial can produce. It means the $30 billion of market value removed on the day was priced against a franchise that the subsequent results showed to be intact.

What did the repairing was the guidance. In the same 4 August announcement that carried the Wegovy pill miss, Novo raised its full-year outlook: adjusted sales growth and adjusted operating profit growth for 2026 are now both expected at 0% to -6% at constant exchange rates, an improvement on the steeper decline previously guided, and the company attributed the upgrade directly to increased expectations for GLP-1 product sales. Q2 adjusted sales grew 7% at CER to DKK 78,488 million, with adjusted operating profit up 11% at CER to DKK 33,389 million.

Read those two facts together and the picture is not the one the 4 August tape suggested. A company does not raise guidance on the strength of GLP-1 demand in the same release where its flagship GLP-1 product is failing. The pill missed a quarterly consensus by about $15 million; the franchise beneath it performed well enough to move the annual outlook up. The market took two sessions to work that out, and the recovery to $47.26 is what working it out looked like.

One caveat belongs here for completeness. Novo recorded DKK 6.3 billion of non-cash impairment charges on intangible pipeline assets in Q2, including DKK 4.0 billion for monlunabant, and has said a further non-cash impairment tied to ZEUS will land in Q3 2026. These are write-downs of pipeline value, not cash costs or operating deterioration, and the company was explicit that the ZEUS outcome does not change its adjusted operating profit outlook for 2026. They belong in the bear column as evidence of how much pipeline optionality has been marked down this year, not as a hit to the earnings the stock is valued on.

The multiple that moves the wrong way

Novo’s earnings arithmetic runs in the opposite direction to most large-cap stories, and it is worth setting out because it is where the bear case actually lives.

Trailing four-quarter EPS is $4.02, made up of $1.02, $1.00, $1.04 and $0.96. At $47.26 that is about 11.8x trailing – cheap for a pharma franchise of this quality. But consensus for the next two quarters is $0.79 and $0.82, both below every quarter Novo has just delivered. Annualise that and forward EPS lands near $3.20, which puts the stock at roughly 14.8x forward.

Read that again: the multiple expands as you move forward, because the earnings are expected to shrink. You are paying more per dollar of profit for a smaller stream of it. That is the mathematical signature of a business the market believes has passed its earnings peak, and it is the exact inverse of the setup we described in our Micron MU stock prediction, where a collapsing forward multiple signals expected earnings decay from a much higher base.

The second tell is the analyst distribution. Novo has beaten consensus in all four of the last quarters, and the average price target now sits at $47.32 against a $47.26 close. Beats are no longer moving targets, because the debate has moved off the income statement entirely. A consensus target one tenth of one percent above the traded price is not a forecast of upside; it is a statement that the sell side has no view worth expressing. The post-results revisions make the point better than the average does: BMO nudged its target up to $47 while keeping Market Perform, Citi trimmed to DKK 310, and Goldman stayed at Hold. Three banks moved, none of them changed their mind.

What management is actually arguing

Chief executive Mike Doustdar spent the days after the print pushing back on the pill narrative specifically, and his argument is more substantive than the usual post-selloff reassurance.

The core of it is a profitability claim. “We would not be able to show a positive growth on the top and the bottom if items like the pill were not doing well and were not profitable,” Doustdar told CNBC, describing the oral franchise’s margins as decent and improving. That matters because the bear reading of the pill is that Novo is buying share by undercutting its own injectable on price – dilutive volume rather than accretive growth.

The supporting data point is the one the market ignored. Novo has passed five million pill prescriptions since launch. The first million took eleven weeks, achieved with no direct competition. The most recent million took four weeks, achieved under competitive pressure. Prescription velocity has therefore roughly tripled at the same time the competitive environment got harder – which is difficult to reconcile with a product that is failing.

Doustdar has also gone further on where this ends: “I could see a future where actually this market is, to a large extent, a pill market,” he said, while noting the launch is only six months old. He has separately said he has no doubt about an eventual share price recovery and has signalled an intent to accelerate R&D to close the perceived gap with Lilly. Whether that acceleration is credible is the single question a Novo investor is really underwriting.

The Lilly problem

No honest assessment of Novo works without stating the competitive position plainly, because the divide between the two companies widened again on these results.

Lilly’s tirzepatide beat CagriSema head-to-head on glycaemic control in February, and Lilly’s most recent quarter reinforced its lead. This is the structural issue: Novo created the obesity category and is now, on the current evidence, the second-best-positioned company in it. For a stock that spent years priced as the franchise owner, moving to challenger status is a re-rating event independent of any single quarter’s revenue.

The counter-argument is one of market size rather than share. The obesity market is large enough, and supply-constrained enough, that second place can still compound for years – particularly if the oral formulation genuinely shifts the delivery mechanism. An injectable duopoly and a pill market are different competitive games, and Novo is further ahead in the second. Readers weighing the adjacent listed exposure to this theme may find our HIMS stock bull and bear case useful, since its economics turn on GLP-1 access rather than on who wins the molecule race.

The bull case: $64

The bull target is $64, implying roughly 35% upside from $47.26. It is not an invented number: it is approximately the 26 January closing peak of $63.98, and it sits almost exactly on the $63.79 high target published on the street. This is a level this stock held six months ago. Two supports.

First, the valuation is undemanding on delivered earnings. At $64 and $4.02 of trailing EPS, the multiple is 15.9x – an ordinary large-pharma rating, not an expansion to anything heroic. The bull case does not need a re-rating premium. It needs the market to stop assuming earnings decline, and the 4 August guidance raise is the first evidence in months pointing that way.

Second, the pill has to be judged on velocity rather than on a single quarter’s consensus comparison. Tripling prescription pace while under competitive attack is the strongest operating datapoint in the release, and if that trajectory holds for two more quarters the $0.79 and $0.82 forward estimates will prove too low. Novo raising guidance twice in a year that included two trial setbacks is consistent with a base business performing better than the share price implies.

The bull case, in one sentence: CagriSema is a pipeline disappointment rather than a franchise failure, and the market has confused the two.

The bear case: $32

The bear target is $32, roughly 32% below the 7 August close, about 9% below the existing 52-week low of $35.12, and below the $40.41 low target on the street. Two derivations converge.

The first is normalised earnings. If the forward consensus trajectory continues and 2027 EPS settles near $3.05 as pricing pressure compounds, a 10.5x multiple – the kind applied to pharma facing competitive erosion rather than growth – produces about $32. Note that this requires no catastrophe, only that the existing downward estimate trend persists for another year.

The second is the Goldman revision taken at face value. Removing $6.8 billion of CagriSema peak revenue and 10% of operating profit through 2030 mechanically lowers any discounted valuation by a similar order. Apply that to a stock already at 11.8x trailing and the low-$30s is where the arithmetic lands.

The specific risk to watch is price, not volume. The Wegovy pill is winning share partly by undercutting Novo’s own injectable, so a mix shift toward the cheaper oral product can grow prescriptions and shrink revenue per patient simultaneously. That is precisely how a company posts record prescription counts and falling EPS in the same year – and the forward consensus already embeds some of it.

Bull versus bear at a glance

What happens next

Three calls, with the reasoning attached.

The Q3 print matters less than the next CagriSema readout. Consensus at $0.79 is set below the last four delivered quarters, so a beat is likely and largely irrelevant – the last four beats moved nothing. The stock is a pipeline instrument now, and the four 8%-plus drops of the past year were all triggered by trial data or pipeline revisions, never by a revenue line.

Watch revenue per prescription, not prescription count. This is the single ratio that separates the two cases. If pill volumes rise while revenue per script falls, the bear thesis of self-cannibalisation is confirmed regardless of how impressive the headline prescription numbers look. If both hold, Doustdar’s profitability argument is validated and the forward estimates are too low.

Expect the target-price cluster to break rather than drift. A $47.32 consensus against a $47.26 price – a gap of six cents – is an unstable equilibrium that reflects analysts declining to take a side. Pipeline stocks do not resolve gradually; the next material readout will force a cluster of revisions in one direction. That argues for sizing around event risk rather than around valuation.

Our read: the market punished the wrong number in August, but it reached a defensible conclusion anyway. The pill data is genuinely better than its reception, and the CagriSema write-down is genuinely worse than the coverage implied. Those roughly offset, which is why we regard neither $64 nor $32 as the base case and treat this as an event-driven holding rather than a valuation one. For a comparison of how a similarly binary, catalyst-dependent name is priced, see our Honeywell Aerospace HONA stock prediction, and for the semiconductor version of the peak-earnings debate, our Texas Instruments TXN price prediction.

Quick take

Frequently asked questions

Why did Novo Nordisk stock fall in August 2026?

NVO fell in two stages: 8.8% on 31 July after a late-stage heart-drug trial missed its key efficacy goal, then 6.0% on 4 August on the heaviest volume of the year. The 4 August move followed Q2 results in which the Wegovy pill missed consensus by about 100 million kroner and CagriSema produced further mixed data, prompting Goldman Sachs to cut the drug’s peak sales forecast from $11.8 billion to $5 billion and downgrade the stock to Neutral. Both moves have since been retraced: the ADRs rose 3.23% on 6 August and a further 2.81% on 7 August to close at $47.26, above where they traded before the ZEUS readout.

Did Novo Nordisk raise or cut guidance at Q2 2026?

It raised guidance. In its 4 August 2026 announcement, Novo said 2026 adjusted sales growth and adjusted operating profit growth are now both expected at 0% to -6% at constant exchange rates, an improvement on the steeper decline previously forecast, and attributed the upgrade to increased expectations for GLP-1 product sales. Q2 adjusted sales rose 7% at CER to DKK 78,488 million and adjusted operating profit rose 11% at CER to DKK 33,389 million. This was the second outlook raise of 2026, and it came in the same release as the Wegovy pill sales miss that drove the headlines.

What is the NVO price target for 2026?

The consensus is $47.32 across 14 analysts, effectively level with the 7 August close of $47.26, with a high of $63.79 and a low of $40.41 and an overall Buy rating. After the Q2 print BMO raised its target to $47 from $45 while keeping Market Perform, Citi cut to DKK 310 from DKK 330, and Goldman Sachs held at Hold. Our bull case is $64 and our bear case is $32.

Is Novo Nordisk stock cheap right now?

On trailing earnings, yes: $4.02 of EPS over the last four quarters puts the ADR at about 11.8x at $47.26. On forward earnings it is less clear, because consensus of $0.79 and $0.82 for the next two quarters implies roughly $3.20 annualised, or 14.8x. The multiple expands going forward because earnings are expected to fall, which is generally a signal that the market believes the peak has passed.

What happened with CagriSema?

CagriSema is Novo’s next-generation obesity candidate. In February 2026 it failed to match Eli Lilly’s tirzepatide on glycaemic control in a head-to-head trial in Type 2 diabetes patients, sending the shares down 16.4% in a single session. Further mixed data accompanied the Q2 2026 results, after which Goldman Sachs reduced its peak sales estimate from $11.8 billion to $5 billion and trimmed operating profit forecasts by roughly 10% for 2026 through 2030.

Is the Wegovy pill actually failing?

The evidence is mixed and the headline framing was harsh. Q2 sales of 3.2 billion kroner missed a 3.3 billion kroner consensus, a shortfall of about $15 million. But cumulative prescriptions have passed five million, and the pace has accelerated sharply: the first million took eleven weeks without competition, the most recent million took four weeks with it. CEO Mike Doustdar has described the pill’s profitability as decent and improving.

How does Novo Nordisk compare with Eli Lilly?

Lilly currently holds the stronger position. Its tirzepatide won the February head-to-head against CagriSema, and its most recent quarter widened the performance gap. Novo created the GLP-1 obesity category but is now competing as the challenger in the injectable market. Its clearest relative advantage is in oral formulation, where the Wegovy pill has a lead that Doustdar argues could eventually reshape the market toward pills.

This article is for information purposes only and does not constitute investment advice. Price and analyst data are as of the 7 August 2026 close. Article updated 8 August 2026.